Afinum announces the formation of the MedTech Laser Group via acquisition of A.R.C. Laser and neoLaser

Afinum has entered into a partnership with the founders of A.R.C. Laser GmbH, Angela Thyzel, and G.N.S. neoLaser Ltd., Gil Shapira, to jointly invest in the formation of an integrated champion for medical laser technologies. As part of the transaction, Afinum acquires a significant majority stake while the founders re-invest in the newly formed entity.

A.R.C. Laser, headquartered in Nuremberg (Germany) and established in 1996, has a long-standing history as a pioneering platform in medical laser technology development. The company offers an extensive range of innovative laser technologies focused on ophthalmic treatments, particularly for glaucoma and cataract procedures. Leveraging its strong R&D capabilities, A.R.C. Laser has successfully diversified its product portfolio to include surgical applications e.g. in Laryngology, Otology, Rhinology, as well as Veterinary medicine. neoLaser, based in Caesarea (close to Tel Aviv, Israel) and founded in 2012, stands out as a fast-growing specialist in laser systems and fibers for Endovenous Laser Ablation and applications in Proctology. neoLaser’s advanced laser solutions have positioned it as a leader in its respective fields, driving significant advancements in patient care and treatment outcomes.

The global market for ophthalmologic and surgical lasers is poised for substantial growth, driven by various secular trends such as aging population, increasing prevalence of relevant diseases, and technological advancements in laser treatments driving adoption across medical disciplines. This market opportunity underscores the strategic rationale behind the formation of the MedTech Laser Group, aimed at capitalizing on these growth drivers to deliver innovative medical solutions.

Under the umbrella of the MedTech Laser Group, A.R.C. Laser and neoLaser will be able to jointly capitalize on this market opportunity. The partnership is designed to harness synergies for further topline growth. The companies will lever their combined strengths to collaborate on research and development, sales and marketing, as well as regulatory matters. The joint growth strategy will emphasize international expansion, an enhanced go to market approach and further driving organizational development. Furthermore, the group will broaden its technology and product portfolio organically and potentially through strategic add-on acquisitions.

This transaction marks the tenth platform investment of the Afinum 9 fund and the second thematic investment in the MedTech sector.